ArQule
Home
Contact
Careers
About
About ArQule
Management
Board of Directors
Business Development
Partners
Scientific Collaborators
Careers
News & Events
Science
Overview
Targeted Approach
Early Stage Programs
Pipeline
Overview
ARQ 531
Miransertib (ARQ 092)
ARQ 751
Derazantinib (ARQ 087)
Oncology Clinical Trials
Rare Diseases Clinical Trials
Patient Access to Investigational Therapies
MOSAIC Clinical Trial
Overview
Patients & Caregivers
Physicians
Publications & Presentations
Investors & Media
Investor Overview
Press Releases
Events & Presentations
Financial Information
Stock Information
Corporate Governance
Investor & Media FAQs
Investor & Media Contact
Twitter
LinkedIn
Results from a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor, in Subjects with Advanced Solid Tumors or Recurrent Malignant Lymphoma - ArQule
Tuesday, September 1, 2015 https://www.arqule.com
Posters and Presentations
News & Events
Company News
Posters and Presentations
Press Releases
Publications
Questions or Concerns?
Please feel free to contact by one of the methods below
Online Form
Call (781) 994-0300
About
Management
Board of Directors
Business Development
Partners
Scientific Collaborators
Careers
News & Events
Pipeline
ARQ 531
Miransertib (ARQ 092)
ARQ 751
Derazantinib (ARQ 087)
Oncology Clinical Trials
Rare Diseases Clinical Trials
Patient Access to Investigational Therapies
Science
Targeted Approach
Early Stage Programs
Publications & Presentations
Investors & Media
Press Releases
Events & Presentations
Financial Information
Stock Information
Corporate Governance
Investor & Media FAQs
Investor & Media Contact
Twitter
LinkedIn
×
Close
What are you looking for?
×
Close
Contact Us
*Required fields
×
Close
Contact Us
*Required fields
×
